Infertility Clinical Trial
Official title:
Sequential E2 Levels Not Ovarian Maximal Diameter Estimates Were Correlated With Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome
To evaluate safety and efficacy of 3-day cetrotide therapy started on day of oocyte
retrieval (Day-0) in women at high-risk for development of ovarian hyperstimulation syndrome
(OHSS) after gonadotropin- releasing hormon agonist induction protocol.
Patients & Methods: Forty-eight women fulfilling inclusion criteria underwent ultrasound
scanning for maximal ovarian diameter (MOD) estimation and ascites grading. Patients
underwent embryo freezing, but study group received 3-day Cetrotide sc injection (0.25
mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value
(Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites
grading were re-evaluated on Day-3, 6 and 8
The current study is conducted at Assisted Reproduction Unit at Almana general Hospital,
kingdom of saudi arabia.and other private centers in Egypt. The study protocol was approved
by the Local Ethical Committee. The study aimed to include women suspected to be at high
risk for development of OHSS during agonist ovarian stimulation protocol.The study includes
only women of couples singed written consent to participate in the study, to undergo embryo
freezing and to postpone for transfer of cryopreserved embryo.
All patients are clinically evaluated for the presence of abdominal pain and if present will
be graduated using a numerical pain visual analogue scale (VAS) with 0 means no pain and 10
means severe intolerable pain. Patients are evaluated for the presence of nausea and/or
vomiting and sense of abdominal distension. Symptoms are scored using verbal analogue scale
as nil, mild, moderate, and severe symptom. Blood samples are obtained under complete
aseptic condition for estimation of serum E2 level and determination of hematocrit value
(Ht%) and total leucocytic count (TLC).
Then, all patients underwent ultrasound scanning for estimation of ovarian measurements that
were represented as the maximal ovarian diameter (MOD) and for ascites grading if present.
Ultrasound scanning is performed using a 5 megahertz vaginal probe , otherwise a 3.5
megahertz, 2.6 megahertz or 5megahertz abdominal probe is used if visualization using a
vaginal probe is compromised. Ascites is graded according to the quantity of fluid
accumulation in the peritoneal cavity with the patient in the anti-Trendelenburg position.
Women fulfilling inclusion criteria were allowed to choose between embryo freezing alone
(Control group) or to additionally receive cetrotide subcutaneous injection in a daily dose
of 0.25 mg started on day of oocyte retrieval for 3 days (Study group). Symptomatic
treatment for associated symptoms as analgesics, antiemetics and antispasmodics are also
prescribed. Patients are categorized according to classification grading of OHSS.
Class Clinical features Biochemical features
Mild - Abdominal distension/ discomfort
- Mild nausea/vomiting
- Diarrhea
- Ovarian size usually < 8 cm No clinically important laboratory findings
Moderate - Mild features plus
- US evidence of ascites - Elevated Ht (>41%)
- Elevated TLC >15,000/ ml
- Hypoproteinemia
Severe - Mild & Moderate features plus
- Clinically detected ascites
- Severe abdominal pain
- Intractable nausea
- Rapid weight gain (>1 kg/24 hr)
- Pleural effusion
- Severe dyspnea
- Oliguria/anuria
- Low blood/central venous pressures
- Syncope
- Venous thrombosis
- Hemoconcentration (Ht >55%)
- TLC >25,000/ ml
- Serum creatinine >1.6 mg/dl
- creatinine clearance <50 ml/min
- Hyponatremia (Na+<135milliequivalent per litre)
- Hypokalemia (K+ < 5 milliequivalent per litre)
- Elevated liver enzymes
Critical - Severe features plus
- Anuria/ Acute renal failure
- Arrhythmia
- Pericardial effusion
- Massive hydrothorax
- Thrombo-embolism
- Arterial thrombosis
- (ARDS)Adult respiratory distress syndrome
- Sepsis - Worsening of biochemical
findings seen with severe OHSS
US: Ultrasound; Ht%:Ht; Hematocrit value; TLC: Total leucocytic count: ARDS; adult
respiratory distress syndrome.
All patients are managed as outpatients unless management of severe symptoms necessitated
hospital admission. Pain scores, serum E2 levels and MOD are evaluated daily. Patients are
evaluated for associated symptoms previously determined during clinical evaluation, ascites
grading and TLC and Ht value were evaluated at 3 and 6 days and on end of the trial on the
8th day after oocyte retrieval.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
| Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
| Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
| Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
| Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
| Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
| Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
| Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
| Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
| Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
| Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
| Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
| Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
| Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
| Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A | |
| Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
| Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A | |
| Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A | |
| Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A | |
| Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A |